DP2 antagonist and uses thereof
    4.
    发明授权
    DP2 antagonist and uses thereof 有权
    DP2拮抗剂及其用途

    公开(公告)号:US08815917B2

    公开(公告)日:2014-08-26

    申请号:US12846690

    申请日:2010-07-29

    CPC分类号: A61K31/195

    摘要: Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

    摘要翻译: 本文描述的是DP2拮抗剂[2' - (3-苄基-1-乙基 - 脲基甲基)-6-甲氧基-4'-三氟甲基 - 联苯-3-基] - 乙酸或其药学上可接受的盐。 还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。 本文还描述了适用于给予哺乳动物包括DP2拮抗剂或其药学上可接受的盐的药物组合物,以及使用这些药物组合物治疗呼吸系统疾病或病症,过敏性疾病或病症,炎性疾病或病症的方法,如 以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症。

    5-lipoxygenase-activating protein inhibitor
    5.
    发明授权
    5-lipoxygenase-activating protein inhibitor 有权
    5-脂氧合酶激活蛋白抑制剂

    公开(公告)号:US08772495B2

    公开(公告)日:2014-07-08

    申请号:US12471106

    申请日:2009-05-22

    IPC分类号: C07D401/14 A61K31/444

    CPC分类号: C07D401/14 A61K31/444

    摘要: Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

    摘要翻译: 本文描述的是FLAP抑制剂3- [3-叔丁基硫烷基-1- [4-(6-乙氧基 - 吡啶-3-基) - 苄基] -5-(5-甲基 - 吡啶-2-基甲氧基)-1H - 吲哚-2-基] -2,2-二甲基 - 丙酸或其药学上可接受的盐。 还描述了制备FLAP抑制剂或其药学上可接受的盐,包括溶剂化物及其多晶型物的方法。 本文还描述了适用于向包括FLAP抑制剂或其药学上可接受的盐的哺乳动物施用的药物组合物,以及使用这些药物组合物治疗呼吸道疾病或其它白三烯依赖性或白细胞三烯介导的病症的方法 或疾病。

    DP2 ANTAGONIST AND USES THEREOF
    7.
    发明申请
    DP2 ANTAGONIST AND USES THEREOF 有权
    DP2拮抗剂及其用途

    公开(公告)号:US20130053444A1

    公开(公告)日:2013-02-28

    申请号:US13519292

    申请日:2011-01-05

    CPC分类号: C07C323/41 C07B2200/13

    摘要: Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

    摘要翻译: 本文描述的是DP2阴离子表面活性剂2-(3-(2 - ((叔丁硫基)甲基)-4-(2,2-二甲基 - 丙酰基氨基)苯氧基)-4-甲氧基苯基)乙酸或其药学上可接受的盐 。 还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。 本文还描述了适用于给予哺乳动物的药物组合物,其包括DP2拮抗剂或其药学上可接受的盐,以及使用这些药物组合物治疗呼吸系统疾病或病症,过敏性疾病或病症,炎性疾病或病症的方法,如 以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症。